Drug Information

Drug General Information
Drug ID
D0X4RN
Former ID
DAP000121
Drug Name
Lidocaine
Synonyms
Alphacaine; Anestacon; Cappicaine; Cuivasil; Dalcaine; Dentipatch; DermaFlex; Dilocaine; Duncaine; EMBOLEX; Esracaine; Gravocain; Isicaina; Isicaine; Jetocaine; LIDOPEN; LQZ; Lanabiotic; Leostesin; Lidocaina; Lidocainum; Lidocaton; Lidoderm; Lignocaine; Lignocainum; Lingocaine; Maricaine; Octocaine; Remicaine; Rucaina; Solcain; Xilina; Xilocaina; Xllina; Xycaine; Xylestesin; Xylesthesin; Xylocain; Xylocaine; Xylocard; Xylocitin; Xylotox; Zingo; After Burn Double Strength Gel; After Burn Double Strength Spray; After Burn Gel; After Burn Spray; Anestacon Jelly; Cito optadren; Emla Cream; Lidocaine Carbonate; Lidocaine Hydrocarbonate; Lidocaine Monohydrochloride; Norwood Sunburn Spray; Rocephin Kit; Solarcaine aloe extraburn relief cream; Xilocaina [Italian]; Xylocaine Dental Ointment; Xylocaine Endotracheal; Xylocaine Test Dose; Xylocaine Viscous; CDS1_000283; L1026_SIGMA; Xylocaine CO2; Dentipatch (TN); ELA-Max; L-Caine; Lida-Mantle; Lidocaina [INN-Spanish]; Lidocaine (VAN); Lidocainum [INN-Latin]; Lidoject-1; Lidoject-2; Octocaine-100; Octocaine-50; Xylocaine (TN); Xylocaine 5% Spinal; Xylocaine-Mpf; Xylocaine-Mpf with Glucose; Xyloneural (free base); Zilactin-L; Lidocaine [USAN:INN:JAN]; Diethylaminoaceto-2,6-xylidide; Lidocaine (JP15/USP/INN); Alfa-Dietilamino-2,6-dimetilacetanilide; Alfa-Dietilamino-2,6-dimetilacetanilide [Italian]; Alpha-Diethylamino-2,6-dimethylacetanilide; Alpha-Diethylaminoaceto-2,6-xylidide; LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE); Omega-Diethylamino-2,6-dimethylacetanilide; Alpha-(Diethylamino)-2,6-acetoxylidide; N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide; N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide; 2-(Diethylamino)-2',6'-acetoxylidide; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide; 2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide; 2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
Drug Type
Small molecular drug
Indication Anesthesia [ICD9: 338; ICD10:R20.0] Approved [537084], [539693]
Dysmenorrhea [ICD9: 625.3; ICD10:N94.4-N94.6] Phase 2 [522279]
Therapeutic Class
Anesthetics
Company
Endo Pharmaceuticals
Structure
Download
2D MOL

3D MOL
Formula
C14H22N2O
InChI
InChI=1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)
InChIKey
NNJVILVZKWQKPM-UHFFFAOYSA-N
CAS Number
CAS 137-58-6
PubChem Compound ID
3676
PubChem Substance ID
9284, 95410, 855682, 3134587, 5152743, 7847424, 7979776, 8152322, 10507335, 11110520, 11111384, 11111385, 11120259, 11120747, 11121235, 11121424, 11121904, 11335349, 11336498, 11360588, 11362493, 11364012, 11365055, 11366574, 11367617, 11369136, 11370257, 11370258, 11372323, 11373218, 11373738, 11375779, 11377298, 11380842, 11461560, 11466078, 11467198, 11485261, 11485836, 11489159, 11491207, 11491885, 11494932, 11511857, 15196283, 24896272, 24896480, 26719632, 26744219, 26751483
ChEBI ID
ChEBI:6456
SuperDrug ATC ID
C01BB01; C05AD01; D04AB01; N01BB02; R02AD02; S01HA07; S02DA01
SuperDrug CAS ID
cas=000137586
Drug Resistance Mutation (DRM)
DRM DRM Info
Target and Pathway
Target(s) Voltage-gated sodium channel Target Info Blocker [537243], [537539]
References
Ref 522279ClinicalTrials.gov (NCT00651313) Efficacy and Safety Study of Lidocaine Vaginal Gel for Recurrent Dysmenorrhea (Painful Periods). U.S. National Institutes of Health.
Ref 537084An absorbable local anesthetic matrix provides several days of functional sciatic nerve blockade. Anesth Analg. 2009 Mar;108(3):1027-33.
Ref 539693(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2623).
Ref 537243Mechanisms of analgesia of intravenous lidocaine. Rev Bras Anestesiol. 2008 May-Jun;58(3):280-6.
Ref 537539Lidocaine inhibits epithelial chemokine secretion via inhibition of nuclear factor kappaB activation. Immunobiology. 2009 Jun 24.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.